scholarly journals Histopathologic Characteristics of Invasive and Non-invasive Ductal Tumors have Relationship with Different Phenotypes of ER / PR Receptors in Breast Cancer Patients

2021 ◽  
Vol 6 (3) ◽  
pp. 181-185
Author(s):  
Rahim Golmohammadi ◽  
Mohammad Reza Mohajeri ◽  
Alireza Mosavi Jarrahi ◽  
Ali Reza Moslem ◽  
Akbar Pejhan ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Hormone Receptors ◽  
Ductal Carcinoma ◽  
Tumor Grade ◽  
Tumor Stage ◽  
Tumor Type ◽  
Breast Cancer Patients ◽  
Non Invasive ◽  
Significant Difference

Objective: Contradictory reports have been published regarding the expression levels of the hormone receptors of estrogen and progesterone (ER / PR) and theirclinical importance in diagnosis of breast cancer. The aim of this study was to evaluate the relationship between pathological features of invasive and non-invasive ductal tumors by different ER / PR phenotypes. Methods: This descriptive-analytical study was performed on 74 specimens of breast cancer referred to Isfahan Hospitals for diagnosis between 2015 - 2018. After fixation of the specimens in formalin, tissue passage, cross section and H / E staining, the specimens were divided into two groups: non- invasive and Invasive ductal Carcinoma. After removing of mask, expression of different ER / PR phenotypes was performed using primary monoclonal antibody and immunohistochemically methods. Results: From 74 malignant specimens, 61 (82.4%) were in the category of invasive ductal tumors and 13 cases (17.6%) were in the category of non-invasive ductal tumors. Out of 73 patients with positive ER or PR phenotype 47 samples (63.5%) had ER + / PR +phenotypes, 6 samples had (8.1%) ER+ / PR –phenotype, 20 samples (27%) had ER- / PR + phenotype and only one sample (1.4%) had the ER- / PR- phenotype and was in the category of invasive ductal tumors. There was not detected ER- / PR- phenotype expression in non-invasive ductal tumor. Further analysis showed that there were not significant difference between ER / PR phenotype and tumor stage (p =0.36) or with tumor Grade (P=0.38), high age of menopause or post menopause (P> 0.05). Conclusion: Our data shows that expression of ER- / PR- phenotype only was detected in invasive ductal tumor. It is thought that the tumor type maybe affects the expression of different types of ER / PR hormone receptor phenotypes in breast cancer patients.

Machine learning methods with salivary metabolomics for breast cancer detection.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. 3135-3135
Author(s):  
Takeshi Murata ◽  
Takako Yanagisawa ◽  
Toshiaki Kurihara ◽  
Miku Kaneko ◽  
Sana Ota ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Machine Learning ◽  
Cancer Patients ◽  
Ductal Carcinoma ◽  
Healthy Controls ◽  
Breast Cancer Patients ◽  
Learning Methods ◽  
Validation Data ◽  
Machine Learning Methods ◽  
Significant Difference

3135 Background: Saliva is non-invasively accessible and informative biological fluid which has high potential for the early diagnosis of various diseases. The aim of this study is to develop machine learning methods and to explore new salivary biomarkers to discriminate breast cancer patients from healthy controls. Methods: We conducted a comprehensive metabolite analysis of saliva samples obtained from 101 patients with invasive carcinoma (IC), 23 patients with ductal carcinoma in situ (DCIS) and 42 healthy controls, using capillary electrophoresis and liquid chromatography with mass spectrometry to quantify hundreds of hydrophilic metabolites. Saliva samples were collected under 9h fasting and were split into training and validation data. Conventional statistical analyses and artificial intelligence-based methods were used to access the discrimination abilities of the quantified metabolite. Multiple logistic regression (MLR) model and an alternative decision tree (ADTree)-based machine learning methods were used. The generalization abilities of these mathematical models were validated in various computational tests, such as cross-validation and resampling methods. Results: Among quantified 260 metabolites, amino acids and polyamines showed significantly elevated in saliva from breast cancer patients, e.g. spermine showed the highest area under the receiver operating characteristic curves (AUC) to discriminate IC from C; 0.766 (95% confidence interval [CI]; 0.671 – 0.840, P < 0.0001). These metabolites showed no significant difference between C and DICS, i.e., these metabolites were elevated only in the samples of IC. The MLR yielded higher AUC to discriminate IC from C; 0.790 (95% CI; 0.699 – 0.859, P < 0.0001). The ADTree with ensemble approach showed the best AUC; 0.912 (95% CI; 0.838 – 0.961, P < 0.0001). In the comparison of these metabolites in the analysis of each subtype, seven metabolites were significantly different between Luminal A-like and Luminal B-like while, but few metabolites were significantly different among the other subtypes. Conclusions: These data indicated the combination of salivary metabolomic profiles including polyamines showed potential ability to screening breast cancer in a non-invasive way.

TRAIL Death Receptor–4 Expression Positively Correlates With the Tumor Grade in Breast Cancer Patients With Invasive Ductal Carcinoma

2007 ◽  
Vol 69 (3) ◽  
pp. 716-723 ◽  
Author(s):  
Ahter D. Sanlioglu ◽  
Aylin F. Korcum ◽  
Elif Pestereli ◽  
Gulgun Erdogan ◽  
Seyda Karaveli ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Invasive Ductal Carcinoma ◽  
Ductal Carcinoma ◽  
Death Receptor ◽  
Tumor Grade ◽  
Breast Cancer Patients ◽  
Death Receptor 4 ◽  
Trail Death Receptor

scholarly journals MMP-2 levels evaluation and their relationship with breast cancer progression.

2020 ◽  
Vol 27 (02) ◽  
pp. 424-430
Author(s):  
Ifrah Yaqoob ◽  
Muhammad Saeed ◽  
Aysha Azhar
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Invasive Ductal Carcinoma ◽  
Cancer Progression ◽  
Ductal Carcinoma ◽  
Histological Type ◽  
Breast Cancer Patients ◽  
Cross Sectional ◽  
Significant Difference ◽  
The University

Matrix metalloproteinases (MMPs) play significant part in the tumor development, metastasis and invasion by proteolytic degradation of basement membrane and extracellular matrix. Hence MMPs can serve as good biomarkers for carcinoma breast particularly MMP-2 in our population. Objectives: To measure the concentrations of MMP-2 in plasma of breast cancer patients and establishing their correlation with stage and grade of the disease. Study Design: Comparative cross sectional. Setting: Surgery department Madinah Teaching Hospital (MTH) and the Pathology department, The University of Faisalabad (TUF), Faisalabad. Period: 1st August, 2017 to 31st December, 2017. Material & Methods: Only females with diagnosed breast cancer disease along with staging and grading were included in the study. Females with incomplete reports, on chemotherapy or radiotherapy or having other diseases like oral squamous cell carcinoma, rheumatoid arthritis etc were excluded. ELISA kit was applied to measure the concentrations of MMP-2 in plasma of the participants. OD values were calculated at 450 nm by ELISA reader placed at Post Graduate Research Laboratory, The University of Faisalabad, Faisalabad. Data was gathered and results were finalized by using SPSS 22 for statistical assessment. Results: Age of 64(72%) breast cancer patients was within range of 30-76yrs and age for 25(28%) healthy females as controls range was 18-70yrs. Difference between ages of cases and controls using t-test was statistically highly significant. Ninety five percent cases showed invasive ductal carcinoma (IDC) as histological type. Range of MMP-2 levels in cases was 80-690 ng/mL with mean 451.02 while range of MMP-2 levels in controls was 65-830ng/mL with mean 329.72 showing statistically significant difference. Relationship of different groups of MMP-2 levels in cases with stages of breast cancer was established using chi-square test which was statistically significant, stage IIB (37.5%) and IIIA (34.4%) tumors showed higher values of MMP-2. Relationship between MMP-2 levels, grade, tumor size and node invasion was nonsignificant statistically. Conclusion: MMP-2 levels were raised in cases in comparison to healthy controls. Age of majority patients was > 45 yrs while the invasive ductal carcinoma was the main histological type. MMP-2 levels were associated with stage of the disease.

scholarly journals Association of EBV (Type 1 and 2) with Histopathological Outcomes in Breast Cancer in Pakistani Women

2021 ◽  
Author(s):  
Yusra Ilyas ◽  
Sanaullah Khan ◽  
Naveed Khan
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Ductal Carcinoma ◽  
Health Sector ◽  
Conclusive Evidence ◽  
Clinical Staging ◽  
Large Sample Size ◽  
Breast Cancer Patients ◽  
Significant Difference ◽  
Ebv Dna

Introduction: Breast cancer is one of the major and frequent tumors in the public health sector globally. The rising global prevalence of breast cancer has aroused attention in a viral etiology. Other than genetic and hormonal roles, viruses like Epstein - Barr virus (EBV) also participate in the development and advancement of breast cancer. Aim: This study was conducted to detect the frequency of EBV genotypes in breast cancer patients and compare it with histopathological breast cancer changes. Methods: Formalin-fixed paraffin-embedded samples of breast cancer (N=60) ages ranged from 22-70 years were collected. EBV DNA was isolated, amplified, typed through PCR, and correlated with histopathological outcomes of breast cancer using SPSS software version 26. Results: Our findings suggest that among breast cancer factors, Invasive ductal carcinoma (IDC) was the most common pathological pattern found among patients (90%), observed statistically significant (p= 0.01275). In regards to clinical staging, 8 (13.3 %) patients diagnosed with stage I, 39 (65 %) with stage II, and 13 (21.6 %) with stage III reported statistically significant association (p=0.0003). EBV DNA was detected in 68.3% (41/60) breast cancer patients, reported a statistically significant difference between the prevalence of EBV in breast cancer patients and normal samples (p = 0.001). Of 41 EBV-positive samples, 40 were EBV-1, while only 1 had EBV-2 infection (p < 0.001). No influence on cancer histology was observed. Regarding the association of breast cancer with EBV, histological type (P =0.209), tumor stage (P = 0.48), tumor grade (0.356), tumor sizes (p= 0.976), age (p= 0.1055), tumor laterality (p= 0.533) and ER/PR status (p=0.773) showed no significant association. Conclusion: EBV-1 is prevalent in breast cancer patients and associated with IDC in the study area. For conclusive evidence, more studies are required based on a large sample size and by using more sensitive techniques.

scholarly journals Investigation of the change in the biological structure of the tumor in metastatic breast cancer

2021 ◽  
Vol 8 (3) ◽  
pp. 171-174
Author(s):  
Veysel Haksoyler ◽  
Tolga Koseci ◽  
Timucin Cil ◽  
Berna Bozkurt Duman ◽  
Polat Olgun ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Cancer Patients ◽  
Hormone Receptors ◽  
Tumor Biology ◽  
Metastatic Breast ◽  
Breast Cancer Patients ◽  
Metastatic Site ◽  
Significant Difference ◽  
Her 2

Objective: When metastasis develops in some breast cancer patients, hormone receptors (HR) and Human Epidermal Growth Factor-2 (Her-2) status can change and the tumor alters its character. We tried to determine the rate of these changes in tumor biology in 110 patients that we followed in our clinic and performed the change of the biopsy from the metastatic site (re-bx). We aimed to determine the biological changes of tumors and, contribute to the literature by examining the relationship of these changes with the adjuvant endocrine treatments (ET) or chemotherapy type (CT). Material and Methods: We included 110 metastatic breast cancer patients in our study. These patients had previously completed their local treatments followed by CT, and those with positive HR completed ET. After the first metastasis developed in the patients, we performed metastasectomy or biopsy from the metastatic site. Results: The median ki-67 value was 25% at the time of primary diagnosis and 30% in re-bx. 20.9% of patients estrogen receptor (ER), 31.8%  of patients progesterone receptor (PR) and 26.3% of patients Her-2 changed when metastasis developed. Conclusions: We found that the metastatic tumor has more aggressive properties than the primary tumor. Adjuvant chemotherapy and endocrine treatments or the location of metastasis did not make a significant difference in tumor biology.

Factors associated with bilateral versus single mastectomy in a diverse, population-based sample of breast cancer patients

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. 6502-6502
Author(s):  
S. Hawley ◽  
R. Jagsi ◽  
A. S. Hamilton ◽  
J. Graff ◽  
J. J. Griggs ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Body Image ◽  
Family History ◽  
Los Angeles ◽  
Cancer Patients ◽  
Ductal Carcinoma ◽  
Tumor Stage ◽  
Bilateral Mastectomy ◽  
Breast Cancer Patients ◽  
Factors Associated

6502 Background: Rates of bilateral mastectomy are increasing in the U.S., even among women with cancer in only one breast. The goal of this analysis was to assess correlates of bilateral mastectomy in a large, racially/ethnically diverse sample of breast cancer patients. Methods: All women with ductal carcinoma-in-situ and a 20% random sample of women with invasive breast cancer aged < 79 years who were diagnosed in 2002 and reported to the Detroit and Los Angeles SEER registries were surveyed shortly after receipt of surgical treatment (response rate, 77.4%; n = 1,844). Patient survey data were merged with SEER data. The primary dependent variable, receipt of bilateral mastectomy, was obtained from patient report and validated by SEER. Independent variables included patient demographics, family history of breast cancer, tumor stage, and patient concerns about recurrence and body image. Logistic regression was used to evaluate factors associated with receipt of all mastectomy (including bilateral) vs. lumpectomy, and then to evaluate bilateral vs. single mastectomy. Results: The mean age was 60 years. 70% were white, 18% Black, and 12% Latina. Overall, 5% of women received bilateral mastectomy (13% of those getting mastectomy). The Table shows factors associated with receipt of any mastectomy vs. lumpectomy (model 1) and bilateral vs. single mastectomy (model 2). Advanced stage and concerns about recurrence were associated with increased odds of any mastectomy while body image concerns were associated with lumpectomy (P<0.05) (model 1). Model 2 shows family history (OR: 3.00; 95% CI 1.36–6.61) and concerns about recurrence (OR: 2.76, 95% CI 1.14–6.68) were associated with greater odds of receiving bilateral vs. single mastectomy. Conclusions: Decision making for any mastectomy vs. lumpectomy is quite different from that for bilateral vs. single mastectomy. The latter appears to be driven by genetic predisposition, but there continues to be a strong influence of women's concerns about recurrence. [Table: see text] No significant financial relationships to disclose.

Overexpression of microRNA-21 in the Serum of Breast Cancer Patients

MicroRNA ◽  
2019 ◽  
Vol 9 (1) ◽  
pp. 58-63
Author(s):  
Batool Savari ◽  
Sohrab Boozarpour ◽  
Maryam Tahmasebi-Birgani ◽  
Hossein Sabouri ◽  
Seyed Mohammad Hosseini
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Cancer Progression ◽  
Tumor Resection ◽  
Tumor Grade ◽  
Healthy Controls ◽  
Breast Cancer Patients ◽  
Serum Samples ◽  
Post Surgery ◽  
Polymerase Chain

Background: Breast cancer is the most common cancer diagnosed in women worldwide. So it seems that there's a good chance of recovery if it's detected in its early stages even before the appearances of symptoms. Recent studies have shown that miRNAs play an important role during cancer progression. These transcripts can be tracked in liquid samples to reveal if cancer exists, for earlier treatment. MicroRNA-21 (miR-21) has been shown to be a key regulator of carcinogenesis, and breast tumor is no exception. Objective: The present study was aimed to track the miR-21 expression level in serum of the breast cancer patients in comparison with that of normal counterparts. Methods: Comparative real-time polymerase chain reaction was applied to determine the levels of expression of miR-21 in the serum samples of 57 participants from which, 42 were the patients with breast cancer including pre-surgery patients (n = 30) and post-surgery patients (n = 12), and the others were the healthy controls (n = 15). Results: MiR-21 was significantly over expressed in the serum of breast cancer patients as compared with healthy controls (P = 0.002). A significant decrease was also observed following tumor resection (P < 0.0001). Moreover, it was found that miR-21 overexpression level was significantly associated with tumor grade (P = 0.004). Conclusion: These findings suggest that miR-21 has the potential to be used as a novel breast cancer biomarker for early detection and prognosis, although further experiments are needed.

scholarly journals Comparing the efficacy and side-effects of PDLASTA® (Pegfilgrastim) with PDGRASTIM® (Filgrastim) in breast cancer patients: a non-inferiority randomized clinical trial

BMC Cancer ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Safa Najafi ◽  
Maryam Ansari ◽  
Vahid Kaveh ◽  
Shahpar Haghighat
Keyword(s):  
Breast Cancer ◽  
Clinical Trial ◽  
Single Dose ◽  
Side Effects ◽  
Randomized Clinical Trial ◽  
Cancer Patients ◽  
Injection Site Reaction ◽  
Study Groups ◽  
Breast Cancer Patients ◽  
Significant Difference

Abstract Background The objective of this study was to compare the efficacy and side effects of a single dose (Pegfilgrastim or PDL) or repeated six daily injections (Filgrastim or PDG) during chemotherapy courses in breast cancer patients in a non-inferiority clinical trial. Methods In this randomized clinical trial, 80 patients were recruited and allocated randomly to two equal arms. In one group, a single subcutaneous dose of PDL was injected the day after receiving the chemotherapy regimen in each cycle. The second arm received a subcutaneous injection of PDG for six consecutive days in each cycle of treatment. The side effects of GCF treatment and its effect on blood parameters were compared in each cycle and during eight cycles of chemotherapy. Results Hematologic parameters showed no significant differences in any of the treatment courses between the two study groups. The comparison of WBC (p = 0.527), Hgb (p = 0.075), Platelet (p = 0.819), Neutrophil (p = 0.575), Lymphocyte (p = 705) and ANC (p = 0.675) changes during the eight courses of treatment also revealed no statistically significant difference between the two study groups. Side effects including headache, injection site reaction and muscle pain had a lower frequency in patients receiving PDL drugs. Conclusion It seems that PDL is non-inferior in efficacy and also less toxic than PDG. Since PDL can be administered in a single dose and is also less costly, it can be regarded as a cost-effective drug for the treatment of chemotherapy-induced neutropenia. Trial registration IRCT20190504043465N1, May 2019.

Sign in / Sign up

Export Citation Format

Share Document